1. Zemanick ET, Emerson J, Thompson V, McNamara S, Morgan W, Gibson RL, Rosenfeld M for the EPIC Study Group. Clinical outcomes after initial Pseudomonas acquisition in cystic fibrosis. Pediatric Pulmonology, 2014 Mar 18.
  2. Daines C, VanDeVanter D, Khan U, Emerson J, Heltshe S, McNamara S, Anstead M, Langkamp M, Doring G, Ratjen F, Ramsey B, Gibson RL, Morgan W, Rosenfeld M, for the EPIC Investigators. Serology as a diagnostic tool for predicting initial Pseudomonas aeruginosa acquisition in children with cystic fibrosis. Journal of Cystic Fibrosis, J Cyst Fibros. 2014 Jul 11.
  3. Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, Retsch-Bogart GZ, Morgan W, Wolter DJ, Pope CE, Houston LS, Kulasekara BR, Khan U, Burns JL, Miller SI, Hoffman LR. Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. American Journal of Respiratory and Critical Care Medicine. 2014 Aug 1;190(3):289-97.
  4. Mayer-Hamblett N, Ramsey BW, Kulasekara H, Wolter DJ, Houston L, Pope C, Kulasekara B, Armbruster C, Burns JL, Retsch-Bogart G, Rosenfeld M, Gibson RL, Miller SI, Khan U, Hoffman LR. Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis. Clinical Infectious Diseases, 2014; 59:624-631.
  5. Mayer-Hamblett N, Rosenfeld M, Treggiari M, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson R, Khan U, Emerson J, Thompson V, Elkin E, Ramsey BW for the EPIC and ESCF Investigators. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatric Pulmonology 2013 Oct;48(10):943-53.
  6. Mayer-Hamblett N, Saiman L, Lands LC, Anstead M, Rosenfeld M, Kloster M, Fisher L, Ratjen F. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinic trials. Contemporary Clinical Trials. 2013 Sep;36(1):99-105.
  7. Anstead M, Heltshe SL, Umer K, Barbieri JT, Langkamp M, Doring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey B. Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. Journal of Cystic Fibrosis 2013 March;12(2):147-53.
  8. Emond MJ, Louie T, Emerson J, Zhao W, Mathias RA, Knowles MR, Rieder M, Tabor HK, Nickerson DA, Barnes KC, NHLBI GO Exome Sequencing Project, ESP-Lung GO Project Group, Gibson RL, Bamshad MJ. Exome sequencing of extreme phenotypes identifies variants in DCTN4 associated with age of onset of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nature Genetics 2012 Jul 8;44(8):886-9.
  9. Rosenfeld M, Bernardo-Ocampo C, Emerson J, Genatossio A, Burns J, Gibson R. Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care. Journal of Cystic Fibrosis 2012 Sep;11(5):446-453.
  10. Rosenfeld M, Emerson J, McNamara M, Thompson V, Ramsey BW, Morgan WJ, Gibson RL, for the EPIC Study Group. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis EPIC Observational cohort. Journal of Cystic Fibrosis 2012 Sep;11(5):456-7.
  11. Mayer-Hamblett N, Kronmal R, Gibson RL, Rosenfeld, M, Retsch-Bogart G, Treggiari MM, Burns J, Khan U, Ramsey B, for the EPIC Investigators. Initial Pseudomonas treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonology 2012; 47:125-34.
  12. Treggiari MM, Retsch-Bogart G,Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Ahrens R, Chatfield BA, Froh DK, Burns J, Rosenfeld M, Ramsey BW, for the EPIC Investigators. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Pediatric and Adolescent Medicine 2011; 165:857-63.
  13. Rosenfeld, M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Guttierrez H, Kanga J, Lahiri T, Noyes B, Ramsey BW, Ren CL, Schechter M, Wagener J, Morgan W, Gibson R, for the EPIC Study Group. The Early Pseudomonas Infection Control (EPIC) Observational Study: Baseline characteristics and associations in a young cohort of children with cystic fibrosis. Pediatric Pulmonology 2010;45(9):934-44.
  14. Treggiari MM, Rosenfeld, M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, EPIC Study Group. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemporary Clinical Trials 2009; 30(3):256-68.